Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Eye Diseases, Hereditary: early-phase trial registry
4 of 11 indexed Eye Diseases, Hereditary trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,577 of 28,707 conditions by registered trial count.
11 US clinical trials · 4 currently recruiting · #1,577 of 28,707 conditions by registered trial count
Eye Diseases, Hereditary: 11 US clinical trials tracked, 4 recruiting.
Eye Diseases, Hereditary is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is ProQR Therapeutics, running 2 of these trials.
Enrollment posture brief
Registry condition eye-diseases-hereditary
OPEN 4 | RECR 36% | LATE 1 | EARLY 5 | RANK #1577 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (36% recruiting · 11 trials)
Eye Diseases, Hereditary lists 4 open slots (36% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Eye Diseases, Hereditary on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Eye Diseases, Hereditary is recruiting below its size-band peers.
4 of 11 indexed trials (36.4%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Eye Diseases, Hereditary research.
ProQR Therapeutics accounts for 2 of 11 trials (18.2%). 7 distinct sponsors appear on at least one study for this condition label.
-
Most Eye Diseases, Hereditary trials plan to enrol fewer than 100 people.
Median target enrolment is 32 among the 11 trials that report a genuine target (sentinel values excluded). 10 of those (90.9%) plan for fewer than 100 participants.
-
Eye Diseases, Hereditary splits between interventional and observational designs.
6 interventional and 5 observational studies make up this index (54.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
11 total, page 1 of 1
Inherited Retinal Degenerative Disease Registry
Foundation Fighting Blindness
NCT02435940
Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene
Laboratoires Thea
NCT06627179
Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)
Laboratoires Thea
NCT06891443
A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001
PYC Therapeutics
NCT06852963
Natural History of PRPF31 Mutation-Associated Retinal Dystrophy
PYC Therapeutics
NCT05573984
Rate of Progression of PCDH15-Related Retinal Degeneration in Usher Syndrome 1F
Jaeb Center for Health Research
NCT04765345
A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)
ProQR Therapeutics
NCT03913143
Non-Interventional Long Term Follow-up Study of Participants Previously Enrolled in the RESTORE Study
Nanoscope Therapeutics
NCT06162585
A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene
ProQR Therapeutics
NCT04123626
Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]
Nanoscope Therapeutics
NCT04945772
Natural History Study of CEP290-Related Retinal Degeneration
Editas Medicine
NCT03396042
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 3 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Eye Diseases, Hereditary records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Eye Diseases, Hereditary trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Eye Diseases, Hereditary page
11 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Eye Diseases, Hereditary trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- ProQR Therapeutics sponsors the most Eye Diseases, Hereditary trials on record, review their full trial history before evaluating a specific study. See ProQR Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Eye Diseases, Hereditary condition card totals 11 registered trials; most-linked intervention sepofarsen; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.